166-180 of 379
Evaluating Gene Therapy for Sickle Cell Disease: Advantages and Barriers
Project Oncology®Evaluating Gene Therapy for Sickle Cell Disease: Advantages and Barriers
David Jacobsohn
Sjögren’s Disease Management: A Decade in Review
Living RheumSjögren’s Disease Management: A Decade in Review
Early Rituximab Use in Sjögren’s Syndrome: A Meta-Analysis Review
Living RheumEarly Rituximab Use in Sjögren’s Syndrome: A Meta-Analysis Review
GeneHarmony: Mapping Shared Genes in Autoimmune Disease
Living RheumGeneHarmony: Mapping Shared Genes in Autoimmune Disease
Sjögren’s Disease Care: Diagnosis and Management Considerations
Living RheumSjögren’s Disease Care: Diagnosis and Management Considerations
Nancy Carteron, MD
Connecting the Dots: Recognizing Systemic Clues in Sjögren’s Disease
Living RheumConnecting the Dots: Recognizing Systemic Clues in Sjögren’s Disease
Nancy Carteron, MD
- advertisement
Preventing Sjögren’s Complications: The Importance of Timely, Accurate Diagnosis
Living RheumPreventing Sjögren’s Complications: The Importance of Timely, Accurate Diagnosis
Nancy Carteron, MD
Detecting Sjögren’s Disease Early: Why Education and Awareness Matters
Living RheumDetecting Sjögren’s Disease Early: Why Education and Awareness Matters
Nancy Carteron, MD
Curative Strategies for Sickle Cell Disease: The Future of Gene Editing
Project Oncology®Curative Strategies for Sickle Cell Disease: The Future of Gene Editing
Alexis Leonard
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
Project Oncology®Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
Recognizing Neonatal FPIES: Key Clues for Early Diagnosis and Treatment
Clinician's RoundtableRecognizing Neonatal FPIES: Key Clues for Early Diagnosis and Treatment
Ryan Quigley
Enhancing IgAN Care: The Importance of a Proactive Approach
Clinician's RoundtableEnhancing IgAN Care: The Importance of a Proactive Approach
Gates B. Colbert, MD
Suneel Udani, MD
- advertisement
Navigating Treatment Goals in IgAN: The Impact of ET-1 and Ang II
Clinician's RoundtableNavigating Treatment Goals in IgAN: The Impact of ET-1 and Ang II
Charles Turck, PharmD, BCPS, BCCCP
Jonathan Barratt, MD, PhD
Shikha Wadhwani, MD
Deciphering the Link: Proteinuria and eGFR Dynamics in IgAN and FSGS
Clinician's RoundtableDeciphering the Link: Proteinuria and eGFR Dynamics in IgAN and FSGS
Gates B. Colbert, MD
Jonathan Barratt, MD, PhD
Innovations in IgAN Care: Addressing Challenges with Therapeutic Advances
Clinician's RoundtableInnovations in IgAN Care: Addressing Challenges with Therapeutic Advances
Charles Turck, PharmD, BCPS, BCCCP
Pietro A. Canetta, MD